India Paroxysmal Nocturnal Hemoglobinuria (PNH) Therapeutics Market Report 2022 to 2030

India Paroxysmal Nocturnal Hemoglobinuria (PNH) Therapeutics Market Analysis

$ 3999

India's Paroxysmal Nocturnal Hemoglobinuria (PNH) Therapeutics market is expected to grow from $67 Mn in 2022 to $181 Mn in 2030 with a CAGR of 13.20% for the year 2022-30. PNH is becoming more common in India, which is anticipated to increase demand for PNH therapies there. The demand for PNH treatments is anticipated to rise as PNH awareness rises in India and more people are likely to seek diagnosis and treatment for the condition. The market is segmented by therapy, diagnostic test, by distribution channels. Some key players in this market include Sun Pharmaceutical, Cipla, Lupin, Aurobindo Pharma, Zydus Cadila Healthcare, Amgen, CSL Behring and Bioverativ.

CATEGORY: Pharmaceuticals GEOGRAPHY: India AUTHOR: Jigyasu Bhandari

Buy Now

India Paroxysmal Nocturnal Hemoglobinuria (PNH) Therapeutics Market Executive Analysis

The India Paroxysmal Nocturnal Hemoglobinuria (PNH) Therapeutics market size is at around $67 Mn in 2022 and is projected to reach $181 Mn in 2030, exhibiting a CAGR of 13.20% during the forecast period. The $10.75 billion remaining for health expenses in India's Union Budget for 2023 represents an increase of $0.28 billion (or 2.71%) from the $10.47 billion set aside in FY23. Prior to being lowered to $9.57 billion for the same period, the Ministry of Health's estimated budget for 2022–2023 was $10.42 billion. The value of assets is predicted to be $10.78 billion this year. This year, India's funding allocation for healthcare decreased from 2.2% to 1.97%.

In India, there are 1.32 cases of PNH per million people. Red blood cells are impacted by the uncommon and deadly blood condition known as Paroxysmal Nocturnal Hemoglobinuria (PNH), which causes them to degrade excessively quickly. Any age, ethnicity, or gender can be affected by PNH, which is brought on by a PIGA gene mutation. PNH can have serious side effects, including blood clots, kidney failure, and life-threatening bone marrow failure. Blood transfusions, blood clot-preventing drugs, and bone marrow transplants are possible treatments for PNH. Blood transfusions may be necessary for PNH patients to replace their damaged red blood cells and raise their haemoglobin levels. People with PNH may be prescribed certain drugs, such as anticoagulants or blood thinners, to prevent blood clots. Patients with severe PNH, particularly those who have bone marrow failure, may be advised to get a bone marrow transplant. To create fresh, healthy blood cells, this surgery includes replacing the damaged bone marrow with healthy donor marrow. A monoclonal antibody called eculizumab targets the protein complement C5, which is essential for the depletion of red blood cells in PNH. In PNH patients, eculizumab can aid in preventing hemolysis and lowering the risk of blood clots. People with PNH could need supportive treatment, such as handling iron overload or taking care of any other potential medical problems.

India Paroxysmal Nocturnal Hemoglobinuria (PNH) Therapeutics Market Analysis

Market Dynamics

Market Growth Drivers

PNH is becoming more common in India, which is anticipated to increase demand for PNH therapies there. The demand for PNH treatments is anticipated to rise as PNH awareness rises in India and more people are likely to seek diagnosis and treatment for the condition. The expansion of the PNH therapeutics market in India is anticipated to be fueled by the discovery of novel medications and technological advances. The Indian government has taken a number of steps to encourage the creation and marketing of innovative treatments for uncommon diseases like PNH. The Indian PNH therapies market is anticipated to develop as a result.

Market Restraints

Patients in India who cannot afford PNH medicines may face major obstacles as a result, which could have a negative impact on the size of the market for producers. The market for PNH treatments may also be constrained by regulatory issues in India, such as the necessity for clinical trials and delays in medication approvals. Manufacturers in the Indian market for PNH therapies may also be constrained by generic medication competition, which could reduce their market share and revenue.

Competitive Landscape

Key Players

Sun Pharmaceutical (IN)
Cipla (IN)
Lupin (IN)
Aurobindo Pharma (IN)
Zydus Cadila Healthcare (IN)
Alexion Pharmaceuticals
Alnylam Pharmaceuticals
Akari Therapeutics
Amgen
CSL Behring
Bioverativ

Healthcare Policies and Regulatory Landscape

The national regulatory organisation in charge of policing the importation, production, and distribution of drugs in India is the Central Drugs Standard Control Organisation (CDSCO). The company is in charge of clinical trial rules, post-marketing surveillance, and drug registration and clearance. The National Health Policy (NHP) describes the government's objectives and plans for enhancing India's access to and provision of healthcare. The strategy places a strong emphasis on the necessity of expanding access to high-quality, reasonably priced healthcare services, including the availability of necessary medications. The Indian government has compiled a list of essential medications called the National List of Essential Medicines (NLEM) that it believes are required to provide for the general public's basic healthcare needs. The list is updated frequently and is used as a resource for purchasing and paying for medications.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

India Paroxysmal Nocturnal Hemoglobinuria (PNH) Therapeutics Market Segmentation

By Therapy

Medication Therapy
Stem Cell Therapy
Blood Transfusion Therapy

By Diagnostic Tests

CBC
LHD
Bone Marrow Examination
Flow Cytometry

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.